Gilead Sciences
GILD
1,682 hedge funds and large institutions have $73.3B invested in Gilead Sciences in 2021 Q4 according to their latest regulatory filings, with 247 funds opening new positions, 638 increasing their positions, 596 reducing their positions, and 103 closing their positions.
140% more first-time investments, than exits
New positions opened: 247 | Existing positions closed: 103
8% more funds holding
Funds holding: 1,563 → 1,682 (+119)
7% more repeat investments, than reductions
Existing positions increased: 638 | Existing positions reduced: 596
5% more capital invested
Capital invested by funds: $70B → $73.3B (+$3.28B)
0.7% more ownership
Funds ownership: 80.09% → 80.79% (+0.7%)
11% less call options, than puts
Call options by funds: $1.78B | Put options by funds: $2.01B
26% less funds holding in top 10
Funds holding in top 10: 31 → 23 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$393M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$289M |
| 3 |
Renaissance Technologies
New York
|
+$247M |
| 4 |
Barclays
London,
United Kingdom
|
+$157M |
| 5 |
State Street
Boston,
Massachusetts
|
+$151M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$509M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$243M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$219M |
| 4 |
Diamond Hill Capital Management
Columbus,
Ohio
|
-$191M |
| 5 |
BlackRock
New York
|
-$139M |
GILD Hedge Fund Activity: Q4 2021 in Review
1,682 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2021, worth a combined $73.3B — up 4.7% from $70B a quarter earlier.
Buyers outnumbered sellers: 247 funds opened new GILD positions and 103 closed out — a net gain of 144 holders — while 638 added to existing stakes and 596 trimmed.
The largest buyer was Capital World Investors, adding an estimated $393M. The largest seller was Capital Research Global Investors, cutting an estimated $509M.
- 1,682 institutional investors held Gilead Sciences (GILD) as of Q4 2021, up from 1,563 in Q3 2021.
- Funds reported $73.3B of Gilead Sciences stock for Q4 2021, up 4.7% quarter-over-quarter.
- 247 funds opened new Gilead Sciences positions in Q4 2021 and 103 closed out, a net change of +144 holders.
- The largest Gilead Sciences buyer in Q4 2021 was Capital World Investors, an estimated $393M added.
- The largest Gilead Sciences seller in Q4 2021 was Capital Research Global Investors, an estimated $509M sold.
Based on aggregated 13F filings for Q4 2021.